NCT00647491已完成2 期
A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
Abbott25 个研究点 分布在 1 个国家目标入组 352 人开始时间: 2004年2月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 352
- 试验地点
- 25
- 主要终点
- ACR20
研究概览
简要总结
The primary objective of this study is to evaluate the safety, efficacy and pharmacokinetics of three doses of adalimumab in adult Japanese subjects with RA
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meet ACR criteria for diagnosis of active RA and have at both screening and baseline visits >10 swollen joints, >12 tender joints.
- •Subjects must have failed prior treatment with one or more DMARDs.
- •A negative (serum) pregnancy test for all female subjects of child-bearing potential at screening and a negative (urine) pregnancy test prior to study drug administration.
- •Body weight less than or equal to 100 kg
排除标准
- •A history of, or current, acute inflammatory joint disease of different origin from RA.
- •Prior treatment with any TNF antagonist, including adalimumab.
- •Any ongoing chronic or active infection or any major episode of infection requiring hospitalization or treatment with IV antibiotics.
- •Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke or any poorly controlled medical condition.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo eow
干预措施: placebo (Biological)
80 mg
Experimental
80 mg adalimumab eow
干预措施: adalimumab (Biological)
40 mg
Experimental
40 mg adalimumab eow
干预措施: adalimumab (Biological)
20 mg
Experimental
20 mg adalimumab eow
干预措施: adalimumab (Biological)
结局指标
主要结局
ACR20
时间窗: Week 24
次要结局
- ACR20(Week12)
- ACR50(Weeks 12 and 24)
- ACR70(Weeks 12 and 24)
研究者
研究点 (25)
Loading locations...
相似试验
已完成
3 期
A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisNCT00853099AbbVie (prior sponsor, Abbott)274
已完成
3 期
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis SuppurativaHidradenitis SuppurativaNCT02904902AbbVie15
已完成
3 期
A Study of Adalimumab in Japanese Subjects With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT00667355Abbott41
已完成
3 期
A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's DiseaseIntestinal Behçet's DiseaseNCT01243671AbbVie (prior sponsor, Abbott)20
未知
2 期
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque PsoriasisPsoriasisJPRN-jRCT2080220270Abbott Japan Co., Ltd.